Industry scouting for best outcome for EU medical technology companies facing dual compliance task
This article was originally published in Clinica
Device companies operating in the EU that are likely to be affected by the overlap in essential requirements under the revised medical devices and active implantables directives (93/42 and 90/385) and the machinery Directive 2006/42 (see Clinica No 1263, p 1) will probably not be able to rely on last-minute help from the EU Council.
You may also be interested in...
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.